Zum Inhalt springen Zur Suche springen

News-Detail

CD19xCD3 T-cell engager blinatumomab effective in refractory generalized myasthenic syndromes.
Tobias Ruck et al., Mol Ther. 2025

Tobias Ruck, Niklas Huntemann, Menekse Öztürk, Stefanie Schreiber, Stefanie Lichtenberg, Lars Masanneck, Christopher Nelke, Hend Ben Moussa, Thomas Ulrych, Marc Seifert, Dimitrios Mougiakakos, Sascha Dietrich, Sven G Meuth.

CD19xCD3 T-cell engager blinatumomab effective in refractory generalized myasthenic syndromes.

Mol Ther. 2025 Sep 3;33(9):4135-4142. doi: 10.1016/j.ymthe.2025.06.042. Epub 2025 Jun 28. PubMed ID: 40583272

 

Further Information:

DOI: 10.1016/j.ymthe.2025.06.042

Sven Meuth

Kategorie/n: NND-Publikationen